Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Auris Medical Inc. (NASDAQ: EARS), a pharmaceutical company that develops therapeutics to highlight the important unrecognized needs in neurology, rhinology, allergy and CNS disorder, shows a decline in its stock during after-hours with apparently no news being available. The company focuses on the treatment of vertigo followed by the development of intranasal betahistine (AM-125, in phase 2). This intranasal betahistine also prevents individuals from antipsychotic-induced weight gain and somnolence (AM-201, post phase 1b).
The company is also working towards the treatment of airborne viruses and allergens (AM-301) for which they are developing a nasal spray in cooperation with their affiliate Altamira Medica. Another of Auris medical’s under development initiatives is their two phase 3 programs;
- Sonsuvi (AM-111), this is for acute inner ear hearing loss.
- Keyzilen (AM-101), this is for the treatment of people suffering from inner ear tinnitus.
On January 29, Auris medical announced, that the company with its affiliate Altamira Medica AG is going to begin the clinical investigation of AM-301 in allergic rhinitis. The process or investigation is going to be an open-label randomized cross-over study that will include 36 patients of allergic rhinitis to grass pollen. In this investigation process, the participants will be examined with a single dose of AM-301 spray or a comparator product with one puff in each nostril. Before this, the patients will be exposed to controlled pollen in an allergen chamber for four hours.
This challenge will be performed for quite a few times with alternate treatments followed by a wash out period. The purpose of this whole investigation process was to find out the efficiency of their product for which the difference in the Total Nasal Symptom Score (TNSS) between the two treatments over the 4-hour exposure will be observed that will serve as the primary or initial efficacy endpoint. Another purpose of the investigation was to depict the clinical non-inferiority of AM-301 in contrast with the comparator product.
The decline in EARS stock is for some unknown reasons because quite recently Auris medical was declared among the few companies with their shares on a gain. Auris medical’s shares have been on a rise for past a year, this decline could be normal pattern that is, downfall of shares after they hike for a while.